No abstract

No abstract

admission supported the clinical diagnosis of mucormycosis. This therefore indicated the initiation of intravenous antifungal therapy while awaiting laboratory results. This lesson was learned from the COVID-19 disaster in India, where multiple cases of COVID-19-related mucormycosis had been reported with a 30% mortality rate. 4 The pan-fungal PCR assay identified Meyerozyma guillermondii (previously known as Candida guilliermondii) on the debridement tissue specimen by nuclear ribosomal repeat region sequencing. Meyerozyma guillermondii is a rare fungal isolate from environmental sources. It can cause opportunistic fungal infections in immunosuppressed hosts, including onychomycosis, superficial cutaneous infections, osteomyelitis and invasive infections. 5 Candida guilliermondii exhibits decreased susceptibility to azole antifungals, which are the most common agents for the treatment of Candida infections. 6 The microorganism has a variable susceptibility to amphotericin B, which explains the dramatic clinical response of our case after 1 week of antifungal treatment. 7 Invasive and oropharyngeal candidiases caused by other species like Candida albicans, tropicalis, parapsilosis, glabrata, dubliniensis and krusei were also reported in COVID-19 patients. 8,9 The report emphasises the significance of COVID-19 fungal co-infections, which necessitates a high index of clinical suspicion for early detection and treatment. This is needed in combination with the prudent use of corticosteroids in COVID-19 patients to minimise the catastrophic complications and fatalities imposed by these co-infections.